ChowChow Cloud Reports 81.3% Revenue Growth in H1 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy CHOW?
Source: Benzinga
- Significant Revenue Growth: ChowChow Cloud reported H1 2025 revenue of HK$178.2 million, an 81.3% year-over-year increase, primarily driven by cloud CDN services and server farm projects from three new customers, indicating strong performance in the rapidly growing cloud services market.
- Net Income Surge: The company achieved a net income of HK$12.5 million for the first half of 2025, up 80% from HK$6.9 million in the prior year, reflecting a substantial enhancement in profitability due to effective cost control and robust market demand.
- Stable Gross Profit: Despite a year-over-year increase in cost of revenues by 81.9% to HK$156.2 million, gross profit rose from HK$12.4 million to HK$22.0 million, with a gross margin remaining stable at approximately 12.3%, showcasing effective cost management.
- Improved Liquidity: As of June 30, 2025, ChowChow reported cash and cash equivalents of approximately HK$11.9 million, up from HK$10.5 million at the end of 2024, indicating sufficient liquidity to support operations and capital needs for at least the next 12 months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHOW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHOW
About CHOW
ChowChow Cloud International Holdings Ltd is an investment holding company mainly engaged in the provision of one-stop cloud solutions business. The Company is engaged in digital transformation consulting services, consisting primarily of cloud suitability assessment, real-time resource management, and strategic planning and advisory. The Company is also engaged in professional information technology (IT) services, including facilitating seamless cloud integration and digital transformation, as well as artificial intelligence (AI)-powered proactive cloud managed services. In addition, the Company is engaged in IT infrastructure solutions, covering on-premise private cloud setups and public cloud integrations.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
- Strong Earnings Performance: Fastly reported earnings of $0.12 per share, surpassing analyst expectations of $0.06, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Significant Revenue Growth: The quarterly revenue reached $172.61 million, exceeding Wall Street's estimate of $161.36 million and up from $140.58 million in the same period last year, demonstrating the company's robust performance amid recovering market demand.
- Stock Price Surge: Fastly's shares jumped 34.8% to $12.55 in pre-market trading, reflecting a positive investor reaction to the earnings report, which may attract more investor interest in its future developments.
- Increased Market Confidence: The strong earnings report not only enhances investor confidence but may also prompt analysts to revise their ratings and price targets for the company, potentially driving further stock price increases.
See More
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More

- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
- Significant Revenue Growth: ChowChow Cloud reported H1 2025 revenue of HK$178.2 million, an 81.3% year-over-year increase, primarily driven by cloud CDN services and server farm projects from three new customers, indicating strong performance in the rapidly growing cloud services market.
- Net Income Surge: The company achieved a net income of HK$12.5 million for the first half of 2025, up 80% from HK$6.9 million in the prior year, reflecting a substantial enhancement in profitability due to effective cost control and robust market demand.
- Stable Gross Profit: Despite a year-over-year increase in cost of revenues by 81.9% to HK$156.2 million, gross profit rose from HK$12.4 million to HK$22.0 million, with a gross margin remaining stable at approximately 12.3%, showcasing effective cost management.
- Improved Liquidity: As of June 30, 2025, ChowChow reported cash and cash equivalents of approximately HK$11.9 million, up from HK$10.5 million at the end of 2024, indicating sufficient liquidity to support operations and capital needs for at least the next 12 months.
See More
- Market Volatility: U.S. stocks traded mixed, with the Dow Jones gaining 0.27% to 48,195.28 points while the NASDAQ fell 0.14% to 23,209.54 points, reflecting uncertainty in the market and divergent investor sentiment.
- Manufacturing PMI Decline: The S&P Global Manufacturing PMI fell from 52.2 to 51.8 in December, indicating a slowdown in manufacturing activity that could impact future economic growth expectations, prompting businesses to adjust strategies to navigate potential market challenges.
- ChowChow Cloud Stock Surge: ChowChow Cloud International Holdings Limited saw its shares rise 29% to $0.78 after reporting year-over-year revenue and net income growth for H1 2025, showcasing the company's strong performance and growth potential in the market.
- Ironwood Pharmaceuticals Guidance Boost: Ironwood Pharmaceuticals, Inc. shares surged 43% to $4.80 following the issuance of FY26 guidance, reflecting the company's confidence in future performance and potentially attracting more investor interest.
See More








